中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
机构
采集方式
内容类型
发表日期
学科主题
筛选

浏览/检索结果: 共22条，第1-10条 帮助

条数/页： 排序方式：
Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities 期刊论文  OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 卷号: 259, 页码: 19
作者:  Wang, Pingyuan;  Zhu, Wen-Ting;  Wang, Yajing;  Song, Shan-Shan;  Xi, Yong
  |  收藏  |  浏览/下载：58/0  |  提交时间：2023/10/17
Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance 期刊论文  OAI收割
EMBO MOLECULAR MEDICINE, 2023, 页码: 24
作者:  Wang, Li-Min;  Wang, Pingyuan;  Chen, Xiao-Min;  Yang, Hui;  Song, Shan-Shan
  |  收藏  |  浏览/下载：21/0  |  提交时间：2023/04/10
Absorption, distribution, metabolism, and excretion of [C-14]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats 期刊论文  OAI收割
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 页码: 12
作者:  Li, Xin-mei;  Zheng, Yuan-dong;  Zhang, Yi-fan;  Huan, Xia-juan;  Yang, Chen
  |  收藏  |  浏览/下载：30/0  |  提交时间：2022/12/13
Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors 期刊论文  OAI收割
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Cao, Guo-Zhen;  Ma, Li-Ying;  Zhang, Zong-Hui;  Wang, Xiao-Lin;  Hua, Jing-Han
  |  收藏  |  浏览/下载：33/0  |  提交时间：2022/12/22
Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone 期刊论文  OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 卷号: 240, 页码: 114574
作者:  Kayumov, Muzaffar;  Jia, Li;  Pardaev, Azizbek;  Song, Shan-Shan;  Mirzaakhmedov, Sharafitdin
  |  收藏  |  浏览/下载：12/0  |  提交时间：2024/03/21
Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion 期刊论文  OAI收割
CANCER BIOLOGY & THERAPY, 2022, 页码: 14
作者:  Guo, Ne;  Li, Meng-Zhu;  Wang, Li-Min;  Chen, Hua-Dong;  Song, Shan-Shan
  |  收藏  |  浏览/下载：27/0  |  提交时间：2022/06/15
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19 期刊论文  OAI收割
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 卷号: 6, 期号: 1, 页码: 16
作者:  Ge, Yiyue;  Tian, Tingzhong;  Huang, Suling;  Wan, Fangping;  Li, Jingxin
  |  收藏  |  浏览/下载：28/0  |  提交时间：2022/06/15
TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models 期刊论文  OAI收割
AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 卷号: 11, 期号: 4, 页码: 1632-1645
作者:  Wang, Lei;  Zhu, Xi;  Li, Lili;  Li, Lin;  Fu, Li
  |  收藏  |  浏览/下载：20/0  |  提交时间：2021/06/11
The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer 期刊论文  OAI收割
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 卷号: 39
作者:  Ma, Liying;  Bian, Xing;  Lin, Wenchu
  |  收藏  |  浏览/下载：29/0  |  提交时间：2020/11/30
Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors 期刊论文  OAI收割
AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 卷号: 10, 期号: 9, 页码: 2813-+
作者:  Chen, Hua-Dong;  Guo, Ne;  Song, Shan-Shan;  Chen, Chuan-Huizi;  Miao, Ze-Hong
  |  收藏  |  浏览/下载：21/0  |  提交时间：2020/12/24